Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC018 for Injection in Participants With Advanced Solid Tumors.

NCT07849218 is registered in ClinicalTrials.gov with Hangzhou DAC Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07849218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07849218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC018 for Injection in Participants With Advanced Solid Tumors.
Lead sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 18, 2026
Completion date
August 31, 2029
Enrollment
110 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors